- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
Accelrys NanoBiology Initiative to Guide Drug Delivery and Diagnostic
Nanodesign Solutions through Academic, Government, Industry Collaboration
Accelrys, Inc. (NASDAQ: ACCL), a
leading provider of scientific solutions, today announced that it will host
a free hour-long web-based seminar introducing the Accelrys NanoBiology
Initiative, an international collaborative framework drawing on academia,
government and industry to address the critical challenges of
nanotechnology-enabled pharmaceutical and diagnostic design.
Focused on bridging the gap between the life sciences and material science at the nanoscale, the NanoBiology Initiative offers members the opportunity to guide the development of core modeling and workflow technologies for speeding innovative products to market. Led by Accelrys NanoBiology Initiative Director, Dr. Deepak Singh, the webinar will provide current and prospective members with an overview of the Initiative as well as a forum for discussion, questions and answers.
Date and Times:
July 13, 2006
Broadcast 1: 14:00 (GMT)/10:00 am (EDT)
Broadcast 2: 10:00 am (PDT)/1:00 pm (EDT)
To register for the Accelrys NanoBiology Initiative Introductory Webinar,
Amid rising competition from generic drug manufacturers, costly drug failures, a stricter regulatory climate and increasing pressure from an aging population, nanotechnology offers the pharmaceutical and diagnostic industries new tools and materials for overcoming those obstacles and driving future growth. As nanotechnology plays an increasingly critical role, it is imperative that scientists and engineers are armed with the powerful modeling, simulation and analytical tools necessary to efficiently assess and develop these highly complex systems. The Accelrys NanoBiology Initiative offers members the opportunity to define and prioritize the most critical challenges in this nascent sector and directly influence the core software solutions.
"Nanomaterials are fundamentally changing the biotechnology landscape, and our goal is to create a new set of computer-based R&D tools capable of anticipating those new needs and adding value every step of the way," said Dr. Deepak Singh. "From multiscale modeling that enables seamless design from the molecular level through full device to workflow platforms that automate R&D best practices across a company, the resulting technologies will provide improved efficiencies, faster time to market, and better return on investment for targeted medicine."
The second of two advanced technology programs Accelrys is currently leading in the area of nanotechnology, the NanoBiology Initiative follows on the success of Accelrys' Nanotechnology Consortium. Established in 2004 to guide the development of technologies for the design and analysis of advanced materials, the Nanotechnology Consortium has led to the creation of a robust suite of multiscale tools for Computer Aided NanoDesign (CAN).
Accelrys, Inc. (ACCL) is a leading provider of software and service solutions for computation, simulation, and the management and mining of scientific data used by biologists, chemists and materials scientists, including nanotechnology researchers, for product design as well as drug discovery and development. Accelrys technology and services are designed to meet the needs of today's leading research organizations. The company is headquartered in San Diego, California. Its materials research and development team is based at its European Headquarters and Centre of Excellence in Cambridge,
For more information, please click here.
Antenna Group (for Accelrys)
Antenna Group (for Accelrys)
Copyright © Accelrys
If you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
Chivalrous Knight Does Pro Bono June 27th, 2015